F-18 Fluciclovine PET/CT for Prostate Cancer

Introduction

F-18 fluciclovine, sold as Axumin, is a synthetic amino-acid PET tracer approved to localize prostate cancer recurrence in men with a rising PSA after prior treatment, and its physics is what makes the study work. The tracer's fast amino-acid kinetics, its renal excretion, and the favorable decay properties of fluorine-18 together dictate a pelvis-first acquisition that must be completed before urinary bladder activity obscures the prostate bed. ¹²

Biochemical recurrence — a rising prostate-specific antigen after surgery or radiation — is a common and frustrating clinical scenario. The PSA says the cancer is back, but conventional CT and bone scan are often negative at the low PSA values where salvage therapy is most effective. Molecular imaging fills that gap, and fluciclovine was one of the first PET agents cleared in the United States specifically for this indication. ²⁷

This article walks through what fluciclovine is, the physics of the fluorine-18 label, the imaging protocol and why its timing matters, how detection depends on PSA, how it compares with PSMA and choline PET, and the QC and radiation-safety framework a facility needs to run the study defensibly. DRPS supports PET/CT programs with PET/CT and nuclear medicine physics testing across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What is fluciclovine?

Fluciclovine is anti-1-amino-3-[F-18]fluorocyclobutane-1-carboxylic acid — historically abbreviated anti-F-18-FACBC — a non-metabolized synthetic analog of the amino acid leucine. It is transported into cells by amino-acid transporters, principally ASCT2 (SLC1A5) and LAT1 (SLC7A5), which are upregulated in prostate cancer. Unlike a metabolic substrate such as FDG, fluciclovine is taken up but not incorporated into protein, so its signal reflects transporter activity rather than glucose metabolism. ¹²

That mechanism matters clinically. Prostate cancer is often not very FDG-avid, so a metabolic tracer is a poor fit. Amino-acid transport, by contrast, is elevated in prostate tumor cells, giving fluciclovine a target that FDG lacks. The FDA approved fluciclovine in 2016 for PET imaging in men with suspected recurrence based on an elevated PSA after prior treatment. ¹

For readers building intuition about PET tracer selection, see our overview of common PET and radiopharmaceutical-therapy isotopes and the companion pieces on Ga-68 PSMA PET imaging and F-18 PSMA PET imaging.

Where fluciclovine fits in the recurrence pathway

Fluciclovine is a restaging tool, not a screening or primary-diagnosis test. It is used when the PSA is rising after definitive treatment and the clinical question is where the disease is — local recurrence in the prostate bed, regional nodes, or distant metastases. That location question drives management: a local recurrence may be salvaged with radiation, whereas nodal or distant disease changes the treatment plan entirely. Multiple trials have shown that fluciclovine PET changes management in a large fraction of patients. ⁹¹⁰

Key Technical Principles

The physics of the fluorine-18 label

Fluorine-18 is the workhorse positron emitter of clinical PET, and its decay properties are central to why fluciclovine is practical. F-18 decays with a half-life of 109.77 minutes, predominantly by positron emission (about 96.7 percent), with the remainder by electron capture, to stable oxygen-18. Each emitted positron annihilates with a nearby electron to produce two 511 keV photons emitted roughly 180 degrees apart — the coincidence signal that PET detects. ³

The activity remaining at time $t$ after assay follows simple exponential decay:

A (t) = A_{0} e^{- λ t}, λ = \frac{ln 2}{T _{1/2}} = \frac{0.693}{109.77 min} = 6.31 \times 1 0^{- 3} min^{- 1}

The 109.77-minute half-life is long enough to allow centralized cyclotron production and delivery to imaging sites — a decisive logistical advantage over shorter-lived tracers — yet short enough to keep patient dose reasonable.

Equally important is the energy of the positron. F-18 emits a relatively low-energy positron (mean energy near 250 keV, maximum near 634 keV), which travels only a short distance before annihilating — a mean positron range on the order of a fraction of a millimeter in soft tissue. Because PET localizes the annihilation point, not the emission point, a short positron range means less blurring and sharper intrinsic spatial resolution. This is a real physics edge of F-18 tracers over higher-energy positron emitters such as gallium-68 (mean positron energy roughly 830 keV), and it is one reason fluciclovine and F-18 PSMA agents can render crisp small lesions. For the underlying detector physics, see PET spatial resolution and positron range. ³

Quantification: activity concentration and SUV

Although fluciclovine is usually read visually, quantification underpins the QC that keeps the scanner honest. The standardized uptake value normalizes measured tissue activity concentration to the injected activity and body weight:

SUV_{b w} = \frac{C ( t ) [ Bq/mL ]}{A _{inj} ( t ) [ Bq ] / BW [ g ]}

where $C (t)$ is the decay-corrected activity concentration in the region of interest at scan time, $A_{inj} (t)$ is the injected activity decay-corrected to the same time, and BW is body weight (assuming a tissue density of 1 g/mL). Every term in that ratio depends on an accurate clock and an accurate dose-calibrator assay — which is exactly why SUV drift is a QC problem, not just a clinical one. See PET SUV quantification and EARL SUV harmonization for the full quantitative chain.

A worked decay example

Suppose a unit dose is assayed at 370 MBq (10 mCi) and the patient is imaged 60 minutes later. The decay factor is:

A (60) = 370 \times e^{- (0.693) (60) /109.77} = 370 \times e^{- 0.379} = 370 \times 0.685 \approx 253 MBq

So about 253 MBq (6.8 mCi) remains at scan time. One full half-life (109.77 minutes) after assay, exactly half remains — 185 MBq (5 mCi). Getting this decay correction right is essential both for accurate SUV and for confirming the administered activity matches the prescription.

Comparison of recurrence-imaging tracers

Property	F-18 fluciclovine (Axumin)	Ga-68 PSMA-11	C-11 choline
Target	Amino-acid transport (ASCT2, LAT1)	Prostate-specific membrane antigen	Choline / phospholipid metabolism
Radionuclide half-life	109.77 min	68 min	20.4 min
Positron energy (mean)	~250 keV (short range)	~830 keV (longer range)	~385 keV
Production / logistics	Cyclotron; centralized delivery	Ge-68/Ga-68 generator, on-site	On-site cyclotron only
Detection at low PSA	Moderate; rises steeply with PSA	Higher, especially at low PSA	Lower than both
Relative strength	Local prostate-bed recurrence near bladder	Overall and nodal sensitivity	Largely superseded

The half-life and positron-energy figures are decay-data values ³; the comparative detection statements are supported by the head-to-head literature discussed below ⁵⁶⁸. The table is a teaching summary — tracer choice at any given facility depends on availability, reimbursement, and the specific clinical question.

Clinical Impact

Detection rises steeply with PSA

The single most important clinical fact about fluciclovine is that its yield depends heavily on the PSA level at the time of imaging. Multiple prospective and real-world series have quantified this:

In a large clinical-practice analysis, whole-body positivity was about 58 percent at PSA below 1 ng/mL, rising to 100 percent at PSA of 2 to under 5 ng/mL, with an overall positivity around 81 percent. ⁴
In a threshold analysis, positive-scan rates rose from about 55 percent below 0.5 ng/mL to over 90 percent above 2.0 ng/mL. ¹¹
The prospective FALCON trial reported an overall detection rate near 56 percent at a median PSA of 0.79 ng/mL, with management changed in about two-thirds of patients. ⁹
The LOCATE trial reported an overall detection rate near 57 percent, with a change in management in a large majority of patients whose scans were positive. ¹⁰

The practical message: fluciclovine is most likely to be informative when the PSA has risen to a level where recurrence is metabolically detectable, and the referring team must weigh the probability of a positive scan against the value of localizing disease early.

How fluciclovine compares with PSMA

PSMA-targeted PET has reshaped prostate cancer imaging, and direct comparisons matter. In a prospective, single-center head-to-head trial in men with early biochemical recurrence (PSA ≤ 2 ng/mL) after prostatectomy, Ga-68 PSMA-11 detected disease in 56 percent of patients versus 26 percent for fluciclovine, with PSMA clearly superior for pelvic nodal and extrapelvic disease. ⁵ Other series are more balanced: one prospective comparison found similar overall detection (about 79 percent for fluciclovine versus 83 percent for PSMA-11), with fluciclovine performing modestly better for local recurrence adjacent to the bladder. ⁶

The consensus that emerges is nuanced. PSMA agents generally offer higher overall and nodal sensitivity, especially at low PSA, which is why they have become first-line in many centers. Fluciclovine remains a validated option, can be advantageous for prostate-bed recurrence near the bladder, and is a fully FDA-approved, widely available study. Against the older tracer C-11 choline, fluciclovine showed significantly higher detection on both patient- and lesion-based analysis. ⁷

Practical Optimization Tips

Fluciclovine imaging is unforgiving of protocol errors, and most of them are physics or timing problems.

1. Protect the early pelvic window

Fluciclovine is renally excreted, so bladder activity builds over the scan. Acquisition therefore starts at mid-thigh and proceeds toward the head, placing the prostate bed in the first bed position within the first few minutes. Begin acquisition about 3 to 5 minutes after the end of injection — earlier risks blood-pool dominance, later risks bladder obscuration. ¹²

2. Control the patient's amino-acid background

Because uptake reflects amino-acid transport, background is sensitive to patient physiology. Per the label and the joint guideline, patients should avoid significant exercise for at least one day before imaging (exercise raises skeletal-muscle uptake) and fast for at least four hours before injection. ¹²

3. Read against blood pool and marrow

Fluciclovine has substantial physiologic blood-pool and bone-marrow uptake. Interpretation uses bone marrow and blood pool as internal reference, with focal uptake exceeding that background considered suspicious. Knowing the normal biodistribution — liver, pancreas, and muscle — prevents false positives. ²

4. Keep the quantitative chain calibrated

Even for a visually read study, the scanner's SUV calibration, the dose-calibrator assay, and the clock synchronization between the injection record and the scanner must be correct. A dose-calibrator that reads high means patients are under-injected relative to the record; a scanner cross-calibration error biases every SUV. Routine dose-calibrator QC and PET/CT daily QC and calibration keep the numbers trustworthy.

5. Minimize CT dose on the fused study

The CT component of a PET/CT provides attenuation correction and anatomic localization. Use the lowest CT technique consistent with those tasks; the diagnostic quality of the CT is usually secondary to the PET. Coordinate CT protocols with your medical physicist to keep CT dose optimized.

Regulatory Considerations

A fluciclovine PET/CT program operates at the intersection of drug-approval, radioactive-material-license, and imaging-accreditation requirements. The tracer itself is an FDA-approved radiopharmaceutical (NDA 208054); its clinical use follows the approved indication and the recommended 370 MBq activity and imaging window. ¹

Key frameworks:

10 CFR Part 35 — Medical Use of Byproduct Material. Fluciclovine is byproduct material, so its receipt, handling, administration, and the authorized-user and RSO responsibilities fall under Part 35 or the equivalent Agreement State program. ¹²
10 CFR Part 20 — Standards for Protection Against Radiation. Occupational and public dose limits govern how the hot lab, uptake room, and injected patient are managed.
Radiation dosimetry. Human dosimetry of fluciclovine gives an effective dose on the order of 14 microsieverts per megabecquerel, roughly 5 mSv for a 370 MBq administration, with the liver among the higher-dose organs — comparable to other routine F-18 PET studies. ⁸
Accreditation. PET/CT scanners performing fluciclovine studies are typically maintained under an accreditation program (such as ACR or IAC) that requires documented scanner QC and an annual medical physicist evaluation.

Jurisdiction depends on the state. Byproduct material such as fluciclovine is regulated by the NRC or an Agreement State. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which reporting, survey, and recordkeeping requirements apply. For the broader radiation-safety picture, see PET/CT and nuclear medicine physics support and our guide to radioactive material license support.

Frequently Asked Questions (FAQs)

What is F-18 fluciclovine (Axumin) used for?

F-18 fluciclovine is a PET radiopharmaceutical approved to image men with suspected prostate cancer recurrence based on an elevated PSA after prior treatment. It is a synthetic amino-acid analog whose uptake reflects amino-acid transport that is upregulated in prostate cancer, helping localize disease when conventional imaging is negative or equivocal.

How much fluciclovine is injected and when is the scan started?

The recommended administered activity is 370 MBq (10 mCi) as a single intravenous bolus. PET acquisition begins about 3 to 5 minutes after the end of injection, starting over the pelvis, because fluciclovine has fast amino-acid kinetics and lesion-to-background contrast is highest early, before urinary bladder activity accumulates.

Why is fluciclovine PET acquired pelvis-first?

Acquisition starts at mid-thigh and moves toward the head so the prostate bed is imaged in the first bed position, within the first few minutes after injection. Fluciclovine is renally excreted, so imaging the pelvis early — before bladder activity builds up — preserves the ability to see local recurrence near the bladder.

Does fluciclovine detection depend on PSA level?

Yes. Detection rises steeply with PSA. Published series report roughly one-third to one-half of scans positive at PSA below 1 ng/mL and above 90 percent positive at PSA greater than 2 ng/mL, so patient selection and PSA context strongly influence yield.

How does fluciclovine compare with PSMA PET?

In a prospective head-to-head trial at low PSA after prostatectomy, Ga-68 PSMA-11 detected more disease than fluciclovine overall and in lymph nodes. Fluciclovine can retain an advantage for local prostate-bed recurrence adjacent to the bladder in some series, but PSMA agents generally show higher sensitivity, especially at low PSA.

What are the physics advantages of the F-18 label?

F-18 has a 109.77-minute half-life that supports centralized production and delivery, and a low mean positron energy near 250 keV that gives a short positron range. The short range limits positron-range blurring, so F-18 tracers support sharper intrinsic PET spatial resolution than higher-energy positron emitters such as Ga-68.

Who oversees the physics and safety of a fluciclovine PET program?

A PET/CT program using fluciclovine operates under a radioactive material license, with a qualified medical physicist and radiation safety officer responsible for scanner QC, dose-calibrator assay, SUV calibration, and radiation safety. DRPS supports these programs with PET/CT physics testing, QC design, and radiation safety consulting.

Key Takeaways

Fluciclovine is an amino-acid tracer, not a metabolic one. Its uptake reflects ASCT2 and LAT1 transporter activity upregulated in prostate cancer, giving it a target FDG lacks.
Timing is physics. The 3-to-5-minute post-injection start and pelvis-first acquisition exist to capture the prostate bed before renal excretion fills the bladder.
The F-18 label is favorable. A 109.77-minute half-life enables centralized delivery, and a low-energy positron gives a short range and sharp resolution.
Yield tracks PSA. Detection climbs from roughly one-third to one-half below PSA 1 ng/mL to above 90 percent above PSA 2 ng/mL.
PSMA generally detects more. Head-to-head, PSMA PET shows higher overall and nodal sensitivity, while fluciclovine can help for prostate-bed recurrence near the bladder.
QC underpins trust. Dose-calibrator assay, SUV calibration, and clock synchronization keep both the administered activity and the images defensible.

Conclusion

F-18 fluciclovine is a good example of how a radiopharmaceutical's physics writes its clinical protocol. The tracer's fast amino-acid kinetics and renal excretion force a pelvis-first, early-start acquisition; the fluorine-18 label's half-life and low positron energy make the study logistically practical and spatially sharp; and its PSA-dependent yield shapes patient selection. In the modern landscape it sits alongside PSMA PET — often second to it in overall sensitivity, but a validated, widely available, FDA-approved option with particular value for local recurrence.

For a facility, running fluciclovine well is a physics and QC commitment as much as a clinical one: accurate assay, calibrated SUV, optimized CT dose, and a defensible radiation-safety program. Facilities that treat those fundamentals as seriously as the interpretation get images they — and their patients — can trust.

How DRPS Can Help

Diagnostic Radiation Physics Services supports PET/CT and nuclear medicine facilities with PET/CT and nuclear medicine physics testing, scanner acceptance and annual surveys, dose-calibrator and QC program design, SUV calibration review, CT physics testing for the fused study, accreditation support, and radiation safety officer and radioactive material license support — all performed by board-certified medical physicists.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong PET program makes accurate quantification and safe practice the easy, repeatable default for the clinical team.

Related Resources

References

U.S. Food and Drug Administration. Axumin (fluciclovine F 18) injection — Prescribing Information. NDA 208054. 2016. accessdata.fda.gov
Nanni C, Zanoni L, Bach-Gansmo T, et al. [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging — version 1.0. Eur J Nucl Med Mol Imaging. 2020;47(3):579-591. doi:10.1007/s00259-019-04614-y. PubMed
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org
Savir-Baruch B, Lovrec P, Solanki AA, et al. Fluorine-18-labeled fluciclovine PET/CT in clinical practice: factors affecting the rate of detection of recurrent prostate cancer. AJR Am J Roentgenol. 2019;213(4):851-858. doi:10.2214/AJR.19.21153. PubMed
Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286-1294. doi:10.1016/S1470-2045(19)30415-2. PubMed
Pernthaler B, Kulnik R, Gstettner C, et al. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET/CT. Clin Nucl Med. 2019;44(10):e566-e573. doi:10.1097/RLU.0000000000002703. PubMed
Nanni C, Schiavina R, Brunocilla E, et al. 18F-Fluciclovine PET/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET/CT. Clin Nucl Med. 2015;40(8):e386-e391. doi:10.1097/RLU.0000000000000849. PubMed
Nye JA, Schuster DM, Yu W, et al. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med. 2007;48(6):1017-1020. doi:10.2967/jnumed.107.040097. PubMed
Scarsbrook AF, Bottomley D, Teoh EJ, et al. Effect of 18F-fluciclovine PET on the management of patients with recurrence of prostate cancer: results from the FALCON trial. Int J Radiat Oncol Biol Phys. 2020;107(2):316-324. doi:10.1016/j.ijrobp.2020.01.050. PubMed
Kim EH, Siegel BA, Teoh EJ, Andriole GL. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: a role for 18F-fluciclovine PET/CT (LOCATE trial). Urol Oncol. 2020;39(6):365.e9-365.e16. doi:10.1016/j.urolonc.2020.10.017. PubMed
Armstrong JM, Martin CR, Dechet C, et al. 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol. 2020;38(7):636.e1-636.e6. doi:10.1016/j.urolonc.2020.03.021. PubMed
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov